These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21148251)

  • 1. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment.
    Wempe MF; Anderson PL
    Drug Metab Dispos; 2011 Mar; 39(3):522-7. PubMed ID: 21148251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
    Kile DA; MaWhinney S; Aquilante CL; Rower JE; Castillo-Mancilla JR; Anderson PL
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1227-34. PubMed ID: 22394315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.
    Anderson PL; Aquilante CL; Gardner EM; Predhomme J; McDaneld P; Bushman LR; Zheng JH; Ray M; MaWhinney S
    J Antimicrob Chemother; 2009 Nov; 64(5):1071-9. PubMed ID: 19710077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.
    Cheng C; Vedananda S; Wu L; Harbeson S; Braman V; Tung R
    J Mass Spectrom; 2013 Sep; 48(9):1019-31. PubMed ID: 24078243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.
    Li F; Lu J; Wang L; Ma X
    Drug Metab Dispos; 2011 Mar; 39(3):394-401. PubMed ID: 21148252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor.
    ter Heine R; Hillebrand MJ; Rosing H; van Gorp EC; Mulder JW; Beijnen JH; Huitema AD
    Drug Metab Dispos; 2009 Sep; 37(9):1826-40. PubMed ID: 19546238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
    Robillard KR; Chan GN; Zhang G; la Porte C; Cameron W; Bendayan R
    Antimicrob Agents Chemother; 2014; 58(3):1713-22. PubMed ID: 24379203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
    Li F; Wang L; Guo GL; Ma X
    Drug Metab Dispos; 2010 May; 38(5):871-8. PubMed ID: 20103582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc: in vitro assessment of drug-drug interaction potential.
    Hyland R; Dickins M; Collins C; Jones H; Jones B
    Br J Clin Pharmacol; 2008 Oct; 66(4):498-507. PubMed ID: 18647303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
    Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
    Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacology, pharmacokinetic features and interactions of atazanavir].
    López-Cortés LF
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():2-8. PubMed ID: 20116610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
    Savic RM; Barrail-Tran A; Duval X; Nembot G; Panhard X; Descamps D; Verstuyft C; Vrijens B; Taburet AM; Goujard C; Mentré F;
    Clin Pharmacol Ther; 2012 Nov; 92(5):575-83. PubMed ID: 23033116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity.
    Li X; Jeso V; Heyward S; Walker GS; Sharma R; Micalizio GC; Cameron MD
    Drug Metab Dispos; 2014 Mar; 42(3):334-42. PubMed ID: 24335391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
    Castillo-Mancilla JR; Aquilante CL; Wempe MF; Smeaton LM; Firnhaber C; LaRosa AM; Kumarasamy N; Andrade A; Baheti G; Fletcher CV; Campbell TB; Haas DW; MaWhinney S; Anderson PL
    J Antimicrob Chemother; 2016 Jun; 71(6):1609-18. PubMed ID: 26892777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
    Sekar VJ; Lefebvre E; De Marez T; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Drugs R D; 2007; 8(4):241-8. PubMed ID: 17596110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.